Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA4 | P22459 | 1/20 | 0.37 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.37 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18919238 | 0.80 | KCNA4 (0.37) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL23528 | 0.74 | — | — | |
| SCHEMBL3545805 | 0.72 | KCNA4 (0.40) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL1471940 | 0.72 | KCNA4 (0.40) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL3265548 | 0.72 | KCNA4 (0.40) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL22470503 | 0.71 | KCNA4 (0.32) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL20504484 | 0.70 | — | — | |
| SCHEMBL194870 | 0.70 | — | — | |
| SCHEMBL22553002 | 0.69 | EPHX1 (0.39) | KCNA4KCNA1KCNAB1 | |
| SCHEMBL10439984 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402862-A1 | IONIZABLE AMINE LIPIDS AND LIPID NANOPARTICLES | INTELLIA THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220162468-A1 | DECORATIVE FILM AND RADIATION CURABLE INKJET INK | 3M INNOVATIVE PROPERTIES COMPANY | 2022-05-26 | — | — | US | disclosed |
| EP-3959191-A1 | IONIZABLE AMINE LIPIDS AND LIPID NANOPARTICLES | Intellia Therapeutics, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| CN-114127044-A | Ionizable amine lipids and lipid nanoparticles | 英特利亚治疗股份有限公司 | 2022-03-01 | — | — | CN | disclosed |
| EP-3946967-A1 | DECORATIVE FILM AND RADIATION CURABLE INKJET INK | 3M Innovative Properties Company (US) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020219876-A1 | IONIZABLE AMINE LIPIDS AND LIPID NANOPARTICLES | INTELLIA THERAPEUTICS, INC. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020194136-A1 | DECORATIVE FILM AND RADIATION CURABLE INKJET INK | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-10-01 | — | — | WO | disclosed |
| US-10759781-B2 | Substituted guanidine derivatives | UBE INDUSTRIES, LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| US-20190152953-A1 | SUBSTITUTED GUANIDINE DERIVATIVES | UBE INDUSTRIES, LTD. (JP) | 2019-05-23 | — | — | US | disclosed |
| EP-3333163-A1 | SUBSTITUTED GUANIDINE DERIVATIVE | UBE Industries, Ltd. (JP) | 2018-06-13 | — | — | EP | disclosed |
| EP-2801574-B1 | ACID ADDUCT SALTS OF SUBSTITUTED PYRIDINE COMPOUND AS CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITORS | DAIICHI SANKYO CO LTD (JP) | 2016-07-27 | — | — | EP | disclosed |
| US-9321747-B2 | Acid addition salt of substituted pyridine compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-04-26 | — | — | US | disclosed |
| US-20150299169-A1 | ACID ADDITION SALT OF SUBSTITUTED PYRIDINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2801574-A1 | ACID ADDUCT SALT OF SUBSTITUTED PYRIDINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-11-12 | — | — | EP | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759781-B2 | Substituted guanidine derivatives | GMPS, GUCY1A1, GUCY1A2 | KCNA4 589/4885KCNA1 712/4885KCNAB1 1046/4885 |
| US-20150299169-A1 | ACID ADDITION SALT OF SUBSTITUTED PYRIDINE COMPOUND | CETP, SLC10A1, MTTP | KCNA4 2248/4885KCNA1 1837/4885KCNAB1 1823/4885 |
| US-20220402862-A1 | IONIZABLE AMINE LIPIDS AND LIPID NANOPARTICLES | PHOSPHO1, SGMS1, SGMS2 | KCNA4 1266/4885KCNA1 2173/4885KCNAB1 2595/4885 |
| US-20190152953-A1 | SUBSTITUTED GUANIDINE DERIVATIVES | GMPS, GUCY1A1, GUCY1A2 | KCNA4 589/4885KCNA1 712/4885KCNAB1 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.